Polar solvents decrease the viscosity of high concentration IgG1 solutions through hydrophobic solvation and interaction: Formulation and biocompatibility considerations

Journal of Pharmaceutical Sciences

Volumn 102, Issue 4, 2013, Pages 1182-1193

  Kamerzell, Tim J ^a,b   Pace, Amanda L ^a   Li, Megan ^a   Danilenko, Dimitry M ^a   Mcdowell, Michelle ^a   Gokarn, Yatin R ^a,c   Wang, Y John ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Calorimetry; Formulation; High concentration; Immunoglobulin; Monoclonal antibody; Preferential interaction; Protein; Spectroscopy; Viscosity

Indexed keywords

DIMETHYL SULFOXIDE; IMMUNOGLOBULIN G1; N,N DIMETHYLACETAMIDE; SOLVENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; CHEMICAL INTERACTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; FEMALE; HEMOLYSIS; HUMAN; HYDROPHOBICITY; INFRARED SPECTROSCOPY; NONHUMAN; PROTEIN STRUCTURE; RAMAN SPECTROMETRY; RAT; SOLVATION; SOLVENT EFFECT; THERMODYNAMICS; TOXICITY TESTING; ULTRAVIOLET SPECTROSCOPY; VISCOSITY;

EID: 84874719195     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23453     Document Type: Article

References (40)

1. Shire SJ. 2009. Formulation and manufacturability of biologics. Curr Opin Biotechnol 20:708-714.
2. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93:1390-1402.
3. Yadav S, Liu J, Shire SJ, Kalonia DS. 2010. Specific interactions in high concentration antibody solutions resulting in high viscosity. J Pharm Sci 99:1152-1168.
4. Kamerzell TJ, Kanai S, Liu J, Shire SJ, Wang YJ. 2009. Increasing IgG concentration modulates the conformational heterogeneity and bonding network that influence solution properties. J Phys Chem B 113:6109-6118.
5. Kanai S, Liu J, Patapoff TW, Shire SJ. 2008. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. J Pharm Sci 97:4219-4227.
6. Liu J, Nguyen MD, Andya JD, Shire SJ. 2005. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 94:1928-1940.
7. Liu J, Shire SJ. 2006. Reduced-viscosity concentrated protein formulations. Patent US6875432B2.
8. Yadav S, Shire SJ, Kalonia DS. 2010. Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. J Pharm Sci 99:4812-4829.
9. Scherer TM, Liu J, Shire SJ, Minton AP. 2010. Intermolecular interactions of IgG1 monoclonal antibodies at high concentrations characterized by light scattering. J Phys Chem B 114:12948-12957.
10. Kamiyama T, Liu HL, Kimura T. 2009. Preferential solvation of lysozyme by dimethyl sulfoxide in binary solutions of water and dimethyl sulfoxide. J Therm Anal Calorim 95:353-359.
11. Duarte AM, van Mierlo CP, Hemminga MA. 2008. Molecular dynamics study of the solvation of an alpha-helical transmembrane peptide by DMSO. J Phys Chem B 112:8664-8671.
12. Kovrigin EL, Potekhin SA. 1997. Preferential solvation changes upon lysozyme heat denaturation in mixed solvents. Biochemistry 36:9195-9199.
13. Johannesson H, Denisov VP, Halle B. 1997. Dimethyl sulfoxide binding to globular proteins: A nuclear magnetic relaxation dispersion study. Protein Sci 6:1756-1763.
14. Chandler D. 2005. Interfaces and the driving force of hydrophobic assembly. Nature 437:640-647.
15. Augustijns P, Brewster ME. 2007. Solvent systems and their selection in pharmaceutics and biopharmaceutics. New York: Springer.
16. Oshida S, Degawa K, Takahashi Y, Akaishi S. 1979. Physico-chemical properties and local toxic effects of injectables. Tohoku J Exp Med 127:301-316.
17. Rowe R. 2003. Handbook of pharmaceutical excipients. Gurnee, Illinois: Pharmaceutical Press.
18. Strickley RG. 2004. Solubilizing excipients in oral and injectable formulations. Pharm Res 21:201-230.
19. Schellman JA. 1975. Macromolecular binding. Biopolymers 14:999-1018.
20. Schellman JA. 1990. A simple model for solvation in mixed solvents. Applications to the stabilization and destabilization of macromolecular structures. Biophys Chem 37:121-140.
21. Plaza del Pino IM, Sanchez-Ruiz JM. 1995. An osmolyte effect on the heat capacity change for protein folding. Biochemistry 34:8621-8630.
22. Kovrigin EL, Potekhin SA. 2000. On the stabilizing action of protein denaturants: Acetonitrile effect on stability of lysozyme in aqueous solutions. Biophys Chem 83:45-59.
23. Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR. 2003. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF case study. J Pharm Sci 92:1805-1820.
24. Kovrigin EL, Potekhin SA. 1996. Microcalorimetric study of the effect of dimethylsulfoxide on the heat denaturation of lysozyme. Biofizika 41:1201-1206.
25. Zheng YJ, Ornstein RL. 1996. Molecular dynamics of subtilisin Carlsberg in aqueous and nonaqueous solutions. Biopolymers 38:791-799.
26. Wen ZQ. 2007. Raman spectroscopy of protein pharmaceuticals. J Pharm Sci 96:2861-2878.
27. Jackson M, Mantsch HH. 1991. Beware of proteins in DMSO. Biochim Biophys Acta 1078:231-235.
28. Xu K, Griebenow K, Klibanov AM. 1997. Correlation between catalytic activity and secondary structure of subtilisin dissolved in organic solvents. Biotechnol Bioeng 56:485-491.
29. Huang P, Dong A, Caughey WS. 1995. Effects of dimethyl sulfoxide, glycerol, and ethylene glycol on secondary structures of cytochrome c and lysozyme as observed by infrared spectroscopy. J Pharm Sci 84:387-392.
30. Rariy RV, Klibanov AM. 1999. Protein refolding in predominantly organic media markedly enhanced by common salts. Biotechnol Bioeng 62:704-710.
31. Barth A, Zscherp C. 2002. What vibrations tell us about proteins. Q Rev Biophys 35:369-430.
32. Cadwallader DE, Phillips JR. 1969. Behavior of erythrocytes in various solvent systems. V. Water-liquid amides. J Pharm Sci 58:1220-1224.
33. Krzyzaniak JF, Alvarez Nunez FA, Raymond DM, Yalkowsky SH. 1997. Lysis of human red blood cells. 4. Comparison of in vitro and in vivo hemolysis data. J Pharm Sci 86:1215-1217.
34. Amin K, Dannenfelser RM. 2006. In vitro hemolysis: Guidance for the pharmaceutical scientist. J Pharm Sci 95:1173-1176.
35. Swanson BN. 1985. Medical use of dimethyl sulfoxide (DMSO). Rev Clin Basic Pharm 5:1-33.
36. Yu ZW, Quinn PJ. 1994. Dimethyl sulphoxide: A review of its applications in cell biology. Biosci Rep 14:259-281.
37. DiStefano V, Klahn JJ. 1965. Observations on the pharmacology and hemolytic activity of dimethyl sulfoxide. Toxicol Appl Pharmacol 7:660-666.
38. Gerhards E, Gibian H. 1967. The metabolism of dimethyl sulfoxide and its metabolic effects in man and animals. Ann N Y Acad Sci 141:65-76.
39. Hall SC, Tan MM, Leonard JJ, Stevenson CL. 1999. Characterization and comparison of leuprolide degradation profiles in water and dimethyl sulfoxide. J Pept Res 53:432-441.
40. Stevenson CL, Leonard JJ, Hall SC. 1999. Effect of peptide concentration and temperature on leuprolide stability in dimethyl sulfoxide. Int J Pharm 191:115-129.